| Vaccines |
1 |
1 |
| Biologic Therapy |
0 |
0.69 |
| Immunocompromise |
0 |
0.98 |
| COVID-19 |
0 |
0.9 |
| COVID-19 Vaccine |
0 |
0.95 |
| Food and Drug Administration (FDA) |
0 |
0.99 |
| Organ Transplantation |
0 |
0.24 |
| Transplantation |
0 |
0.2 |
| Cancer |
0 |
0.14 |
| Chemotherapy |
0 |
0.14 |
| Geriatrics |
0 |
0.14 |
| Immunization |
0 |
0.14 |
| Stress |
0 |
0.14 |
| Stem Cell Research and Therapy |
0 |
0.11 |
| Antimetabolite |
0 |
0.07 |
| Asplenia |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Canada |
0 |
0.07 |
| CAR-T |
0 |
0.07 |
| Centers for Disease Control and Prevention |
0 |
0.07 |
| Child |
0 |
0.07 |
| Chronic Disease |
0 |
0.07 |
| Concerns of Elderly |
0 |
0.07 |
| Corticosteroids |
0 |
0.07 |
| Dialysis |
0 |
0.07 |
| Epidemiology |
0 |
0.07 |
| Genetic Disorders |
0 |
0.07 |
| Genomic Medicine |
0 |
0.07 |
| Hand |
0 |
0.07 |
| Health Care Quality, Access, and Evaluation |
0 |
0.07 |
| Immunodeficiency |
0 |
0.07 |
| Immunosuppressive Therapy |
0 |
0.07 |
| Long-Term Care |
0 |
0.07 |
| Outpatient Clinic |
0 |
0.07 |
| Ovarian Cancer |
0 |
0.07 |
| Peer Review |
0 |
0.07 |
| Prognosis |
0 |
0.07 |
| Residency |
0 |
0.07 |
| Severe Acute Respiratory Syndrome |
0 |
0.07 |
| Spleen |
0 |
0.07 |
| Tennessee |
0 |
0.07 |
| Travel Medicine |
0 |
0.07 |
| Tumor |
0 |
0.07 |
| UK Site Content |
0 |
0.07 |
| Primary Immunodeficiency |
0 |
0.05 |
| Acute Respiratory Distress Syndrome |
0 |
0.03 |
| Health Care Reform |
0 |
0.03 |
| Hemodialysis |
0 |
0.03 |
| Social Determinants of Health |
0 |
0.03 |